BMS-986470

PreclinicalSmall molecule

Bristol-Myers Squibb

BMS-986470 is one of 3 small molecule programs targeting Anemia, Sickle Cell. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anemia, Sickle CellRecruiting

Anemia, Sickle CellPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Anemia, Sickle Cell

#DrugCompanyPhaseTrials

Pepcid

KKenvue Brands

Preclinical

1 2

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 3

BMS-986470

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Anemia, Sickle Cell

NCT06481306

Clinical

Trials by Indication[1]

Anemia, Sickle Cell1 trial

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT06481306·224 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMS-986470. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986470 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986470. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bristol-Myers Squibb

BMS-986470

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Anemia, Sickle Cell1 trial

References

Drug Info

Quick Facts

Related News